Covered recipient · General Payments record
MARK A SOCINSKI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$421,935.74
296 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $262,458.25 | 123 |
| Consulting Fee | $103,427.75 | 32 |
| Honoraria | $39,562.50 | 20 |
| Travel and Lodging | $13,895.26 | 76 |
| Food and Beverage | $2,591.98 | 45 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $93,216.55 | 76 |
| AstraZeneca Pharmaceuticals LP | $70,323.40 | 44 |
| JAZZ PHARMACEUTICALS INC. | $60,898.51 | 55 |
| G1 Therapeutics, Inc. | $40,804.27 | 21 |
| Regeneron Healthcare Solutions, Inc. | $35,621.10 | 31 |
| Eli Lilly and Company | $24,062.50 | 3 |
| Janssen Biotech, Inc. | $18,745.00 | 11 |
| GENZYME CORPORATION | $16,901.56 | 9 |
| Amgen Inc. | $16,562.25 | 10 |
| Blueprint Medicines Corporation | $12,072.60 | 11 |
| Genentech USA, Inc. | $11,880.00 | 6 |
| Novartis Pharmaceuticals Corporation | $3,125.00 | 2 |
| AbbVie Inc. | $3,000.00 | 3 |
| EMD Serono, Inc. | $2,760.00 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,555.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $1,938.00 | 2 |
| F. Hoffmann-La Roche AG | $1,815.00 | 1 |
| Janssen Global Services, LLC | $1,320.00 | 1 |
| Mylan Inc. | $1,274.00 | 3 |
| Coherus Biosciences Inc. | $900.00 | 1 |
| Acrotech Biopharma LLC | $816.00 | 1 |
| Regeneron Pharmaceuticals, Inc. | $685.00 | 1 |
| Exelixis Inc. | $660.00 | 1 |
Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARK A SOCINSKI
NPI 1740341726 · CMS profile ID 1266401
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ORLANDO, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARK A SOCINSKI, NPI 1740341726, CMS profile ID 1266401. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MARK A SOCINSKI, NPI 1740341726, CMS profile ID 1266401. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MARK A SOCINSKI, NPI 1740341726, CMS profile ID 1266401, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
296 matching records · $421,935.74 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 296.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $40.00 | 11/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818636889 | CMS |
| Lilly USA, LLC | $23.71 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818643897 | CMS |
| Lilly USA, LLC | $72.00 | 11/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818651739 | CMS |
| JAZZ PHARMACEUTICALS INC. | $124.73 | 11/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845604803 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,460.00 | 11/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820266705 | CMS |
| JAZZ PHARMACEUTICALS INC. | $110.00 | 11/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845604805 | CMS |
| Genentech USA, Inc. | $1,980.00 | 11/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835945851 | CMS |
| Genentech USA, Inc. | $1,980.00 | 11/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835945855 | CMS |
| Lilly USA, LLC | $14.36 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818643901 | CMS |
| Eli Lilly and Company | $18,812.50 | 11/08/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818600169 | CMS |
| Genentech USA, Inc. | $1,980.00 | 11/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835945857 | CMS |
| JAZZ PHARMACEUTICALS INC. | $545.18 | 11/04/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845604391 | CMS |
| JAZZ PHARMACEUTICALS INC. | $34.92 | 11/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845604381 | CMS |
| JAZZ PHARMACEUTICALS INC. | $34.42 | 11/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845604383 | CMS |
| JAZZ PHARMACEUTICALS INC. | $92.48 | 11/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845604385 | CMS |
| Amgen Inc. | $433.00 | 11/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826386921 | CMS |
| G1 Therapeutics, Inc. | $750.00 | 10/29/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102485 | CMS |
| Regeneron Healthcare Solutions, Inc. | $55.00 | 10/28/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627009 | CMS |
| Regeneron Healthcare Solutions, Inc. | $55.00 | 10/28/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627011 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.54 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627013 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2.44 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627015 | CMS |
| Regeneron Healthcare Solutions, Inc. | $181.14 | 10/28/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627017 | CMS |
| G1 Therapeutics, Inc. | $14.84 | 10/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102445 | CMS |
| G1 Therapeutics, Inc. | $69.99 | 10/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102453 | CMS |
| G1 Therapeutics, Inc. | $4,450.00 | 10/27/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102469 | CMS |
| G1 Therapeutics, Inc. | $30.99 | 10/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102501 | CMS |
| G1 Therapeutics, Inc. | $180.00 | 10/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102503 | CMS |
| G1 Therapeutics, Inc. | $95.70 | 10/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102507 | CMS |
| G1 Therapeutics, Inc. | $239.98 | 10/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102511 | CMS |
| G1 Therapeutics, Inc. | $437.88 | 10/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 840102515 | CMS |
| JAZZ PHARMACEUTICALS INC. | $221.77 | 10/27/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845609115 | CMS |
| Amgen Inc. | $2,165.00 | 10/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826386937 | CMS |
| Lilly USA, LLC | $3,075.00 | 10/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818600181 | CMS |
| Lilly USA, LLC | $3,500.00 | 10/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818634631 | CMS |
| Amgen Inc. | $2,165.00 | 10/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826386931 | CMS |
| Lilly USA, LLC | $1,750.00 | 10/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818666613 | CMS |
| Lilly USA, LLC | $94.57 | 10/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818586105 | CMS |
| Lilly USA, LLC | $390.72 | 10/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818608423 | CMS |
| Lilly USA, LLC | $47.04 | 10/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818643895 | CMS |
| Lilly USA, LLC | $122.03 | 10/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818651755 | CMS |
| Amgen Inc. | $2,165.00 | 10/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826386925 | CMS |
| Amgen Inc. | $2,165.00 | 10/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826386933 | CMS |
| Coherus Biosciences Inc. | $900.00 | 10/19/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855095813 | CMS |
| JAZZ PHARMACEUTICALS INC. | $380.00 | 10/19/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845601579 | CMS |
| JAZZ PHARMACEUTICALS INC. | $4,740.00 | 10/19/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845601581 | CMS |
| Lilly USA, LLC | $7,000.00 | 10/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818634627 | CMS |
| Lilly USA, LLC | $43.02 | 10/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818634639 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,095.00 | 10/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820266699 | CMS |
| JAZZ PHARMACEUTICALS INC. | $47.85 | 10/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845602991 | CMS |
| JAZZ PHARMACEUTICALS INC. | $62.00 | 10/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845602993 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $601,733.94 | 158 |
| PY2024 | Recipient | $4,283.48 | 3 |
| PY2024 | Principal investigator | $771,116.31 | 283 |
| PY2023 | Recipient | $4,221.06 | 2 |
| PY2023 | Principal investigator | $290,089.93 | 47 |
| PY2022 | Recipient | $14,436.87 | 3 |
| PY2022 | Principal investigator | $143,948.28 | 34 |
| PY2021 | Recipient | $8,869.29 | 6 |
| PY2021 | Principal investigator | $929,103.51 | 35 |
| PY2020 | Recipient | $27,146.10 | 14 |
| PY2020 | Principal investigator | $402,348.75 | 15 |
| PY2019 | Recipient | $8,029.00 | 2 |
| PY2019 | Principal investigator | $130,615.92 | 37 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
158 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | BeOne Medicines Ltd. | $874.00 | 11/26/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190341577 |
| Principal investigator 1 | BeOne Medicines Ltd. | $250.00 | 09/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327329 |
| Principal investigator 1 | BeOne Medicines Ltd. | $250.00 | 09/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327333 |
| Principal investigator 1 | BeOne Medicines Ltd. | $6,076.00 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327051 |
| Principal investigator 1 | BeOne Medicines Ltd. | $812.00 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327257 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,042.00 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327277 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,672.00 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327281 |
| Principal investigator 1 | BeOne Medicines Ltd. | $20,790.00 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327313 |
| Principal investigator 1 | BeOne Medicines Ltd. | $17,437.00 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327323 |
| Principal investigator 1 | BeOne Medicines Ltd. | $328.99 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327341 |
| Principal investigator 1 | BeOne Medicines Ltd. | $101.00 | 09/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331771 |
| Principal investigator 1 | BeOne Medicines Ltd. | $500.00 | 09/22/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327117 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,491.00 | 09/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327041 |
| Principal investigator 1 | BeOne Medicines Ltd. | $203.00 | 09/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327295 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,612.00 | 09/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327325 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,038.00 | 09/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331767 |
| Principal investigator 1 | BeOne Medicines Ltd. | $707.00 | 08/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327059 |
| Principal investigator 1 | BeOne Medicines Ltd. | $203.00 | 08/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327091 |
| Principal investigator 1 | BeOne Medicines Ltd. | $250.00 | 08/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327109 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,970.00 | 08/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327111 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,491.00 | 08/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327243 |
| Principal investigator 1 | BeOne Medicines Ltd. | $338.00 | 08/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327339 |
| Principal investigator 1 | BeOne Medicines Ltd. | $101.00 | 08/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327227 |
| Principal investigator 1 | BeOne Medicines Ltd. | $16,408.99 | 08/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327223 |
| Principal investigator 1 | BeOne Medicines Ltd. | $324.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327067 |
| Principal investigator 1 | BeOne Medicines Ltd. | $750.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327217 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,491.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327251 |
| Principal investigator 1 | BeOne Medicines Ltd. | $135.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327255 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,014.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327267 |
| Principal investigator 1 | BeOne Medicines Ltd. | $972.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327269 |
| Principal investigator 1 | BeOne Medicines Ltd. | $203.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327275 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,323.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327289 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,468.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327331 |
| Principal investigator 1 | BeOne Medicines Ltd. | $406.00 | 08/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327337 |
| Principal investigator 1 | BeOne Medicines Ltd. | $676.00 | 08/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327045 |
| Principal investigator 1 | BeOne Medicines Ltd. | $250.00 | 07/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327061 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,502.00 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327069 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,513.00 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327119 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,502.00 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327237 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,513.00 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327283 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,513.00 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327335 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,502.00 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331777 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,989.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326212 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,633.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326224 |
| Principal investigator 1 | BeOne Medicines Ltd. | $247.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326226 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,970.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326236 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,989.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326238 |
| Principal investigator 1 | BeOne Medicines Ltd. | $34.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326244 |
| Principal investigator 1 | BeOne Medicines Ltd. | $895.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326248 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,989.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326250 |
| Principal investigator 1 | BeOne Medicines Ltd. | $338.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331237 |
| Principal investigator 1 | BeOne Medicines Ltd. | $247.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331241 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,989.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331243 |
| Principal investigator 1 | BeOne Medicines Ltd. | $338.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331269 |
| Principal investigator 1 | BeOne Medicines Ltd. | $124.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331275 |
| Principal investigator 1 | BeOne Medicines Ltd. | $203.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331277 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,989.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338723 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,989.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338727 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,223.99 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338731 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,970.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338736 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,889.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338743 |
| Principal investigator 1 | BeOne Medicines Ltd. | $324.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338747 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,989.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338758 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,491.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343016 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,556.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343037 |
| Principal investigator 1 | BeOne Medicines Ltd. | $34.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343050 |
| Principal investigator 1 | BeOne Medicines Ltd. | $120.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343062 |
| Principal investigator 1 | BeOne Medicines Ltd. | $203.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343070 |
| Principal investigator 1 | BeOne Medicines Ltd. | $45.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343074 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,612.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343078 |
| Principal investigator 1 | BeOne Medicines Ltd. | $45.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343082 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,982.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343085 |
| Principal investigator 1 | Genentech, Inc. | $24,762.00 | 06/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211539695 |
| Principal investigator 1 | Genentech, Inc. | $476.00 | 06/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211539700 |
| Principal investigator 1 | BeOne Medicines Ltd. | $8,910.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326222 |
| Principal investigator 1 | BeOne Medicines Ltd. | $203.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326228 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,352.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326240 |
| Principal investigator 1 | BeOne Medicines Ltd. | $88.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331273 |
| Principal investigator 1 | BeOne Medicines Ltd. | $7,836.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190338719 |
| Principal investigator 1 | BeOne Medicines Ltd. | $648.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343033 |
| Principal investigator 1 | BeOne Medicines Ltd. | $200.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343055 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,963.99 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343059 |
| Principal investigator 1 | BeiGene, Ltd. | $2,814.00 | 05/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322876 |
| Principal investigator 1 | BeiGene, Ltd. | $2,814.00 | 05/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325030 |
| Principal investigator 1 | BeiGene, Ltd. | $203.00 | 05/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325044 |
| Principal investigator 1 | BeiGene, Ltd. | $676.00 | 05/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325056 |
| Principal investigator 1 | BeiGene, Ltd. | $4,982.00 | 05/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325058 |
| Principal investigator 1 | BeiGene, Ltd. | $1,380.00 | 05/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325014 |
| Principal investigator 1 | BeiGene, Ltd. | $250.00 | 05/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325032 |
| Principal investigator 1 | BeiGene, Ltd. | $1,200.00 | 05/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325618 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 05/16/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320708 |
| Principal investigator 1 | BeiGene, Ltd. | $338.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320680 |
| Principal investigator 1 | BeiGene, Ltd. | $2,970.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320682 |
| Principal investigator 1 | BeiGene, Ltd. | $5,224.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320684 |
| Principal investigator 1 | BeiGene, Ltd. | $338.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320686 |
| Principal investigator 1 | BeiGene, Ltd. | $7,473.03 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320692 |
| Principal investigator 1 | BeiGene, Ltd. | $302.98 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320704 |
| Principal investigator 1 | BeiGene, Ltd. | $203.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320706 |
| Principal investigator 1 | BeiGene, Ltd. | $5,224.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320718 |
| Principal investigator 1 | BeiGene, Ltd. | $203.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320720 |
| Principal investigator 1 | BeiGene, Ltd. | $2,491.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320724 |
| Principal investigator 1 | BeiGene, Ltd. | $2,612.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320726 |
| Principal investigator 1 | BeiGene, Ltd. | $338.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320730 |
| Principal investigator 1 | BeiGene, Ltd. | $2,491.01 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322884 |
| Principal investigator 1 | BeiGene, Ltd. | $2,612.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322890 |
| Principal investigator 1 | BeiGene, Ltd. | $2,491.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322894 |
| Principal investigator 1 | BeiGene, Ltd. | $101.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322898 |
| Principal investigator 1 | BeiGene, Ltd. | $250.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322946 |
| Principal investigator 1 | BeiGene, Ltd. | $2,970.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322948 |
| Principal investigator 1 | BeiGene, Ltd. | $406.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325022 |
| Principal investigator 1 | BeiGene, Ltd. | $2,633.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325028 |
| Principal investigator 1 | BeiGene, Ltd. | $5,940.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325046 |
| Principal investigator 1 | BeiGene, Ltd. | $2,612.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325060 |
| Principal investigator 1 | BeiGene, Ltd. | $5,639.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325596 |
| Principal investigator 1 | BeiGene, Ltd. | $101.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325598 |
| Principal investigator 1 | BeiGene, Ltd. | $4,982.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325602 |
| Principal investigator 1 | BeiGene, Ltd. | $1,014.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325610 |
| Principal investigator 1 | BeiGene, Ltd. | $609.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325612 |
| Principal investigator 1 | BeiGene, Ltd. | $2,491.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325614 |
| Principal investigator 1 | BeiGene, Ltd. | $2,970.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325622 |
| Principal investigator 1 | BeiGene, Ltd. | $250.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325636 |
| Principal investigator 1 | BeiGene, Ltd. | $2,633.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325640 |
| Principal investigator 1 | BeiGene, Ltd. | $7,473.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325642 |
| Principal investigator 1 | BeiGene, Ltd. | $2,970.00 | 05/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325648 |
| Principal investigator 1 | Genentech, Inc. | $1,200.00 | 05/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211539722 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $600.00 | 04/28/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236530164 |
| Principal investigator 1 | BeiGene, Ltd. | $676.00 | 04/25/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320694 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 04/25/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320716 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 04/25/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322882 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 04/25/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325608 |
| Principal investigator 1 | BeiGene, Ltd. | $250.00 | 04/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322896 |
| Principal investigator 1 | Genentech, Inc. | $3,239.00 | 04/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211539725 |
| Principal investigator 1 | Genentech, Inc. | $7,631.98 | 03/26/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211539714 |
| Principal investigator 1 | BeiGene, Ltd. | $7,473.00 | 03/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190319970 |
| Principal investigator 1 | BeiGene, Ltd. | $101.00 | 03/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190319998 |
| Principal investigator 1 | BeiGene, Ltd. | $47.00 | 03/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320012 |
| Principal investigator 1 | BeiGene, Ltd. | $1,014.00 | 03/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320068 |
| Principal investigator 1 | BeiGene, Ltd. | $91.00 | 03/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324292 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 03/12/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320098 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 03/12/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324284 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 03/12/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324650 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 03/12/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324700 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 02/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190319950 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 02/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320082 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 02/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324164 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 02/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324170 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 02/21/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324304 |
| Principal investigator 1 | BeiGene, Ltd. | $250.00 | 02/05/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324638 |
| Principal investigator 1 | BeiGene, Ltd. | $47.00 | 02/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324172 |
| Principal investigator 1 | BeiGene, Ltd. | $2,491.00 | 02/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324290 |
| Principal investigator 1 | BeiGene, Ltd. | $338.00 | 02/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324658 |
| Principal investigator 1 | AstraZeneca UK Limited | $2,044.58 | 01/29/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST) | No dispute reported | 06/30/2026 | 1185543224 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 01/29/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190319954 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 01/29/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190319992 |
| Principal investigator 1 | BeiGene, Ltd. | $2,989.00 | 01/29/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190319996 |
| Principal investigator 1 | BeiGene, Ltd. | $250.00 | 01/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324280 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $500.00 | 01/15/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | No dispute reported | 06/30/2026 | 1185543226 |
| Principal investigator 1 | Eli Lilly and Company | $196,103.40 | 01/06/2025 | Covered Recipient Teaching Hospital ADVENTHEALTH ORLANDO | A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1187871627 |